LaRive Bio is a clinical development and licensing organization founded in 2021 and based in Zug. We seek to identify, license in/acquire, develop and license out molecules in areas of significant unmet medical need, applying an abbreviated regulatory pathway. At present, focus lies on Neurology.

Products, services, technology

We aim for developing treatment options by means of improving on existing first line treatment in areas of significant unmet medical need.  CLX-106, a promising molecule for treatment of Multiple Sclerosis, was selected and will enter phase I clinical development with a 505(b)2 regulatory pathway.

Cooperation possibilities

The core team in Zug cooperates with top tier CRO’s, regulatory and manufacturing partners.

Some insights
Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2021
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in